Tesamorelin Injection

[13 October 2014]

Products Affected - Description

Egrifta, EMD Serono
2 mg vial in 30 count boxes with diluent (NDC 44087-2011-02) - discontinued
Egrifta, Theratechnologies
2 mg vial in 30 count boxes with diluent (NDC 62064-0021-30) - discontinued

Reason for the Shortage

  • EMD Serono had Egrifta 2 mg vials on shortage due to manufacturing delays.
  • EMD Serono discontinued Egrifta 1 mg vials in May 2013.
  • Theratechnologies acquired Egrifta from EMD Serono in the spring of 2014.
  • Theratechnologies had Egrifta 2 mg vials on shortage due to manufacturing delays. They have reverted to the 1 mg vials from the 2 mg vials and have begun manufacturing this new presentation.

Available Products

No presentation is available.
Egrifta, Theratechnologies
1 mg vial in 30 count boxes with diluent (NDC 62064-0011-60)

Estimated Resupply Dates

Theratechnologies has Egrifta available through specialty pharmacies. Patients must enroll in the Egrifta Assist Program (844-347-4382).

Related Shortages


October 13, 2014; September 16, 2014; September 4, 2014; June 23, 2014; April 15, 2014; March 17, 2014; February 5, 2014; January 6, 2014; December 3, 2013; October 30, 2013, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
ASHP Product Listing